Evidence map›Paper›PMID 28707796›Full record

ArticleAlimentary pharmacology & therapeutics2017

Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin.

D J Gracie, A C Ford

2 registry-linked trialsOpen access · bronzeAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00695643 phase3terminatednot on this map

Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

TypeinterventionalSponsorDr. Falk Pharma GmbHRan2008 to 2012Enrolled345ConditionsDiverticulitisArmsMesalazine, Placebo
NCT01038739 phase3terminatednot on this map

Double-blind, Dose-response, Randomised, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

TypeinterventionalSponsorDr. Falk Pharma GmbHRan2010 to 2013Enrolled330ConditionsDiverticulitisArmsMesalazine, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

D J GracieLeeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.ORCID 0000-0001-9616-981X
A C FordLeeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.ORCID 0000-0001-6371-4359
University of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DiverticulitisMesalamineDiverticulitis, ColonicHumansMesalamine

Identifiers

PMID28707796
OpenAlexW2735655667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.